Breaking News Instant updates and real-time market news.

AINV

Apollo Investment

$5.64

0.04 (0.71%)

, AZN

AstraZeneca

$36.43

-0.07 (-0.19%)

20:25
05/17/18
05/17
20:25
05/17/18
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include Apollo Investment (AINV), consensus 16c... AstraZeneca (AZN), consensus 35c... Campbell Soup (CPB), consensus 61c... Deere (DE), consensus $3.30.

AINV

Apollo Investment

$5.64

0.04 (0.71%)

AZN

AstraZeneca

$36.43

-0.07 (-0.19%)

CPB

Campbell Soup

$39.23

-0.24 (-0.61%)

DE

Deere

$146.85

-0.505 (-0.34%)

  • 18

    May

  • 18

    May

  • 18

    May

  • 30

    May

  • 05

    Jun

AINV Apollo Investment
$5.64

0.04 (0.71%)

02/08/18
WELS
02/08/18
UPGRADE
WELS
Outperform
Apollo Investment upgraded to Outperform on turnaround at Wells Fargo
Wells Fargo analyst Jonathan Bock last night upgraded Apollo Investment to Outperform from Market Perform with a $6.25 price target. The company continues to execute on its turnaround under new management, Bock told investors in a research note. He views the current valuation as attractive.
02/07/18
WELS
02/07/18
UPGRADE
WELS
Outperform
Apollo Investment upgraded to Outperform from Market Perform at Wells Fargo
11/07/17
RAJA
11/07/17
UPGRADE
Target $7
RAJA
Outperform
Apollo Investment upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Robert Dodd upgraded Apollo Investment to Outperform and established a $7 price target following the Q2 report saying its strategy shift into more proprietary debt positions has improved credit quality and the underlying value of the portfolio.
11/03/17
COMP
11/03/17
UPGRADE
COMP
Buy
Apollo Investment upgraded to Buy from Neutral at Compass Point
AZN AstraZeneca
$36.43

-0.07 (-0.19%)

04/06/18
PIPR
04/06/18
NO CHANGE
PIPR
Neutral
Clovis approval underscores rising competition facing Zejula, says Piper Jaffray
Prior to today's announcement that Clovis' (CLVS) label for its PARP inhibitor Rubraca has been expanded to include maintenance therapy in ovarian cancer, AstraZeneca's (AZN) Lynparza and Tesaro's (TSRO) Zejula were the only two PARP inhibitors approved in the maintenance setting, noted Piper Jaffray analyst Christopher Raymond. While Clovis' approval is not a surprise, it does underscore the intensifying competitive pressure facing Zejula, he said. Raymond, who said PARP inhibitors will primarily be differentiated on safety and added that this does not favor Zejula, keeps a Neutral rating on Tesaro.
03/19/18
03/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Unilever (UN, UL) upgraded to Neutral from Sell at Goldman Sachs with the firm's analyst saying valuation reflects growth challenges. 2. AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies with analyst Ian Hilliker saying the company is at a "turning point." 3. Dr Pepper Snapple (DPS) upgraded to Outperform from Sector Perform at RBC Capital saying that some investors have struggled to justify the strategic rationale of the company's Keurig deal, but he sees "several value creation drivers" including leverage in the growing coffee category, improvements for the core Keurig brand, and the prospects for higher cash flow conversion. 4. Oshkosh (OSK) upgraded to Buy from Hold while Cummins (CMI) upgraded to Hold from Sell at Deutsche Bank. 5. HarborOne Bancorp (HONE) upgraded to Buy from Hold at Sandler O'Neill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/19/18
JEFF
03/19/18
UPGRADE
JEFF
Buy
AstraZeneca upgraded to Buy from Hold at Jefferies
Jefferies analyst Ian Hilliker upgraded AstraZeneca to Buy and raised his price target for the shares to 5,600p from 5,075p. The company is at a "turning point," Hilliker tells investors in a research note. He believes accelerating new product launches and improving margins should deliver over 20% core earnings growth in the mid-term. Recovering growth, driven by the underlying business warrants a "modest mid-term premium valuation," the analyst contends.
03/14/18
HCWC
03/14/18
NO CHANGE
Target $6
HCWC
Buy
Advaxis drug unlikely culprit of patient death, says H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth lowered his price target for Advaxis (ADXS) to $6 from $23 after the FDA placed a clinical hold on the Phase 1/2 study investigating the combination of the company's axalimogene filolisbac and AstraZeneca's (AZN) durvalumab for the treatment of HPV-associated cervical and head and neck cancers. Based on its previous safety profile, axalimogene is unlikely to be the cause of death for this patient, Ramakanth tells investors in a research note. The analyst, however, notes that it would likely take several months before the FDA is able to reach a decision and lift the clinical hold. He anticipates a one-to-two quarter delay to the axal plus durva combination therapy program but keeps a Buy rating on Advaxis shares.
CPB Campbell Soup
$39.23

-0.24 (-0.61%)

04/18/18
PIPR
04/18/18
NO CHANGE
Target $43
PIPR
Underweight
Piper maintains Underweight on Campbell Soup, cuts target to $43
Piper Jaffray analyst Michael Lavery expects higher steel costs and lower than expected Snyder-Lance operating contribution to weigh on Campbell Soup's fiscal 2019 earnings growth. The analyst expects growth of just 1.0%-1.5% and maintains an Underweight rating on the shares. He lowered his price target for Campbell Soup to $43 from $45.
04/16/18
04/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Delphi Technologies (DLPH) initiated with an Outperform at Cowen. 2. BorgWarner (BWA) initiated with an Outperform at Cowen. 3. Campbell Soup (CPB) reinstated with an Underperform at Credit Suisse. 4. Visteon (VC) initiated with an Outperform at Cowen. 5. TPG RE Finance (TRTX) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/16/18
FBCO
04/16/18
INITIATION
Target $40
FBCO
Underperform
Campbell Soup reinstated with an Underperform at Credit Suisse
Credit Suisse analyst Robert Moskow reinstated Campbell Soup with an Underperform rating and $40 price target following the completion of the Snyder's Lance acquisition.
04/13/18
04/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dropbox (DBX) initiated with a Reduce at Nomura Instinet. 2. Horizon Global (HZN) initiated with a Buy at B. Riley FBR. 3. Sonoco Products (SON) initiated with a Buy at UBS. 4. Campbell Soup (CPB) reinstated with a Sell at Goldman Sachs. 5. Celgene (CELG) resumed with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
DE Deere
$146.85

-0.505 (-0.34%)

05/07/18
05/07/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McDonald's (MCD) and AutoZone (AZO) were upgraded to Conviction Buy from Buy at Goldman Sachs. 2. Eaton (ETN), Deere (DE), and Terex (TEX) were upgraded to Outperform from In Line at Evercore ISI. 3. LendingTree (TREE) and Santander Consumer (SC) were upgraded to Buy from Neutral at UBS, while Discover (DFS) was upgraded to Neutral from Sell. 4. First Industrial Realty (FR) upgraded to Buy from Neutral at Mizuho with analyst Richard Anderson saying he sees a "path for outperformance from here" with the valuation at "floor" levels. 5. Illumina (ILMN) upgraded to Overweight from Equal Weight at Barclays with analyst Jack Meehan saying he believes his firm's NovaSeq customer survey indicates "substantial elasticity of demand." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/07/18
EVER
05/07/18
UPGRADE
Target $187
EVER
Outperform
Deere, Eaton, Terex upgraded to Outperform at Evercore ISI
As reported earlier, Evercore ISI analyst David Raso upgraded Deere (DE), Eaton (ETN), and Terex (TEX) to Outperform from In Line while adjusting their profit target to $187 from $166, $85 from $88, and $48 from $44 as part of his broader research note on Machinery stocks. Raso notes that the recent multiple compression in the sector has created an attractive entry point for these select names, while adding that the market's implied peak valuation in 2019 should actually be extended to 2021. The analyst further contends that "absolute industry volume" remains low, higher commodity prices relative to the rise in U.S. Treasury yields are a "positive" for the relative performance of the machinery sector, and that the market underestimates these companies' cash deployment power given the longer duration of the economic cycle. As part of his research note, the analyst also downgraded Parker Hannifin (PH) to In Line from Outperform and reduced his price target to $187 from $198, citing the company's reduced operating margin expectations and relatively higher valuation within its peer group.
05/07/18
EVER
05/07/18
UPGRADE
EVER
Outperform
Deere upgraded to Outperform from In Line at Evercore ISI
05/03/18
BOFA
05/03/18
UPGRADE
Target $159
BOFA
Buy
Deere upgraded to Buy better grain, increased equipment demand at BofA/Merrill
As previously reported, BofA/Merrill upgraded Cummins to Buy from Neutral and reduced his price target to $159 from $172. Analyst Ross Gilardi said shares have materially underperformed the sector over the last two months on Chinese trade war concerns, increasing input costs, and a slow down in South American farm equipment demand. Gilardi said grain prices have been acting better and a soybean trade war with China seems unlikely. Additionally, analyst is also encouraged by the improvement in used farm equipment prices and sees the potential for South American demand to re-accelerate in 2018.

TODAY'S FREE FLY STORIES

PM

Philip Morris

$79.91

-0.55 (-0.68%)

18:47
09/25/18
09/25
18:47
09/25/18
18:47
Periodicals
Philip Morris hits streets to sell older smokers on new devices, Bloomberg says »

Philip Morris is moving a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

URBN

Urban Outfitters

$40.06

-0.32 (-0.79%)

18:45
09/25/18
09/25
18:45
09/25/18
18:45
Initiation
Urban Outfitters initiated  »

Urban Outfitters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

SVMK

SurveyMonkey

$0.00

(0.00%)

18:35
09/25/18
09/25
18:35
09/25/18
18:35
Syndicate
SurveyMonkey 15M share IPO priced at $12.00 »

The shares are expected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

LULU

Lululemon

$158.42

1.04 (0.66%)

18:34
09/25/18
09/25
18:34
09/25/18
18:34
Initiation
Lululemon initiated  »

Lululemon initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROL

Rollins

$62.46

0.74 (1.20%)

, ANDV

Andeavor

$157.60

-1.41 (-0.89%)

18:30
09/25/18
09/25
18:30
09/25/18
18:30
Hot Stocks
S&P announces changes to S&P 400, 500, 600 indices »

S&P Dow Jones Indices…

ROL

Rollins

$62.46

0.74 (1.20%)

ANDV

Andeavor

$157.60

-1.41 (-0.89%)

INGN

Inogen

$258.49

5.5 (2.17%)

VNDA

Vanda Pharmaceuticals

$20.70

0.3 (1.47%)

MPC

Marathon Petroleum

$85.04

-0.78 (-0.91%)

GTX

Garrett Motion

$0.00

(0.00%)

ACET

Aceto

$2.83

-0.09 (-3.08%)

HON

Honeywell

$165.59

0.12 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 01

    Oct

  • 09

    Oct

  • 19

    Oct

  • 27

    Nov

TJX

TJX

$110.33

0.605 (0.55%)

18:27
09/25/18
09/25
18:27
09/25/18
18:27
Initiation
TJX initiated  »

TJX initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYH

Community Health

$3.41

-0.08 (-2.29%)

18:25
09/25/18
09/25
18:25
09/25/18
18:25
Hot Stocks
Breaking Hot Stocks news story on Community Health »

Community Health up 3.2%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFL

Aflac

$47.69

-0.01 (-0.02%)

18:25
09/25/18
09/25
18:25
09/25/18
18:25
Conference/Events
Aflac to hold financial analysts briefing »

Financial Analysts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

TPC

Tutor Perini

$19.55

-0.275 (-1.39%)

18:12
09/25/18
09/25
18:12
09/25/18
18:12
Hot Stocks
Tutor Perini awarded $82M aircraft maintenance contract »

Tutor Perin announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLTH

Nobilis Health

$0.95

-0.0494 (-4.94%)

18:01
09/25/18
09/25
18:01
09/25/18
18:01
Hot Stocks
Nobilis Health names Kenny Klein new CFO »

Nobilis Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

FPAY

FlexShopper

$1.16

-0.69 (-37.30%)

17:57
09/25/18
09/25
17:57
09/25/18
17:57
Syndicate
FlexShopper 10M share Secondary priced at $1.00 »

Credit Suisse acted as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FPAY

FlexShopper

$1.16

-0.69 (-37.30%)

17:55
09/25/18
09/25
17:55
09/25/18
17:55
Syndicate
FlexShopper 10M unit Secondary priced at $1.00 »

ThinkEquity, a division…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$84.79

0.52 (0.62%)

17:48
09/25/18
09/25
17:48
09/25/18
17:48
Hot Stocks
Nike says Jordan brand 'incredibly strong' in China »

Says relationship with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

NKE

Nike

$84.79

0.52 (0.62%)

17:45
09/25/18
09/25
17:45
09/25/18
17:45
Hot Stocks
Breaking Hot Stocks news story on Nike »

Nike says recent ad…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

CYH

Community Health

$3.41

-0.08 (-2.29%)

17:43
09/25/18
09/25
17:43
09/25/18
17:43
Hot Stocks
Community Health reaches settlement pact with DOJ over HMA probe »

Community Health Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$84.79

0.52 (0.62%)

17:39
09/25/18
09/25
17:39
09/25/18
17:39
Hot Stocks
Breaking Hot Stocks news story on Nike »

Nike sees FY19 gross…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

NKE

Nike

$84.79

0.52 (0.62%)

17:39
09/25/18
09/25
17:39
09/25/18
17:39
Earnings
Nike sees 'strong' sequential revenue growth in Q2 »

Sees Q2 gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

KBH

KB Home

$25.29

-0.24 (-0.94%)

17:38
09/25/18
09/25
17:38
09/25/18
17:38
Hot Stocks
KB Home CEO sees slower sales in higher priced homes »

Comments from Q3 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

MTBC

Medical Transcription Billing

$4.96

0.2 (4.20%)

17:36
09/25/18
09/25
17:36
09/25/18
17:36
Syndicate
Breaking Syndicate news story on Medical Transcription Billing »

Medical Transcription…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$84.79

0.52 (0.62%)

17:34
09/25/18
09/25
17:34
09/25/18
17:34
Hot Stocks
Breaking Hot Stocks news story on Nike »

Nike says has seen 17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

GTX

Garrett Motion

$0.00

(0.00%)

, ACET

Aceto

$2.83

-0.09 (-3.08%)

17:30
09/25/18
09/25
17:30
09/25/18
17:30
Hot Stocks
Garrett Motion to replace Aceto in S&P 600 at open on October 2 »

Honeywell (HON) is…

GTX

Garrett Motion

$0.00

(0.00%)

ACET

Aceto

$2.83

-0.09 (-3.08%)

HON

Honeywell

$165.59

0.12 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 19

    Oct

NKE

Nike

$84.79

0.52 (0.62%)

17:27
09/25/18
09/25
17:27
09/25/18
17:27
Hot Stocks
Nike says has returned to 'strong, sustainable growth' in North America »

Says facets of live story…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

RBNC

Reliant Bancorp

$25.91

-0.27 (-1.03%)

17:25
09/25/18
09/25
17:25
09/25/18
17:25
Hot Stocks
Reliant Bancorp raises quarterly cash dividend 33% from last year »

Reliant Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNDA

Vanda Pharmaceuticals

$20.70

0.3 (1.47%)

, INGN

Inogen

$258.49

5.5 (2.17%)

17:25
09/25/18
09/25
17:25
09/25/18
17:25
Hot Stocks
Breaking Hot Stocks news story on Vanda Pharmaceuticals, Inogen »

Vanda Pharmaceuticals to…

VNDA

Vanda Pharmaceuticals

$20.70

0.3 (1.47%)

INGN

Inogen

$258.49

5.5 (2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 09

    Oct

  • 27

    Nov

INGN

Inogen

$258.49

5.5 (2.17%)

, ROL

Rollins

$62.46

0.74 (1.20%)

17:23
09/25/18
09/25
17:23
09/25/18
17:23
Hot Stocks
Breaking Hot Stocks news story on Inogen, Rollins »

Inogen to replace Rollins…

INGN

Inogen

$258.49

5.5 (2.17%)

ROL

Rollins

$62.46

0.74 (1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 09

    Oct

  • 27

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.